BIEL (Bioelectronics) EBITDA Margin %: 0.00% (As of . 20)


What is Bioelectronics EBITDA Margin %?

Bioelectronics BIEL -16.67% EBITDA Margin % is 0.00% as of . 20.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bioelectronics's EBITDA for the three months ended in . 20 was $0.00 Mil. Bioelectronics's Revenue for the three months ended in . 20 was $0.00 Mil. Therefore, Bioelectronics's EBITDA margin for the quarter that ended in . 20 was 0.00%.

Bioelectronics  (OTCPK:BIEL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Bioelectronics EBITDA Margin % Related Terms

Bioelectronics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Bioelectronics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioelectronics EBITDA Margin % Chart

Bioelectronics Annual Data
Trend
EBITDA Margin %

Bioelectronics Quarterly Data
EBITDA Margin %

BIEL vs NUVPF, ADMD, RSPI: EBITDA Margin % Comparison

For the Medical Devices subindustry, Bioelectronics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioelectronics EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioelectronics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Bioelectronics's EBITDA Margin % falls into.


Bioelectronics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Bioelectronics's EBITDA Margin % for the fiscal year that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (A: . 20 )/Revenue (A: . 20 )
=/
= %

Bioelectronics's EBITDA Margin % for the quarter that ended in . 20 is calculated as

EBITDA Margin %=EBITDA (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Bioelectronics (BIEL) has a EBITDA Margin % of 0.00% as of . 20. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioelectronics and its competitors.
Is Bioelectronics' EBITDA Margin % too high?
Bioelectronics' current EBITDA Margin % is 0.00%.
How does Bioelectronics' EBITDA Margin % compare to NUVPF and ADMD?
Bioelectronics' EBITDA Margin % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bioelectronics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioelectronics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioelectronics stock overvalued right now?
Bioelectronics (BIEL) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bioelectronics (BIEL), the current EBITDA Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bioelectronics Business Description

Address 3880 Roundtree Road, Suite 1, Jefferson, MD, USA, 21755
Bioelectronics Corp is an electroceutical company. The company develops wearable, neuromodulation devices to safely mitigate neurological diseases and improve quality of life. Its product line includes Actipatch Musculoskeletal Pain Therapy, Allay menstrual pain therapy, Smart insole heel pain therapy, and Recovery RX post operative and Chronic wounds therapy. It sells its products to wholesale distributors, directly to hospitals and clinics, and to consumers. develops & commercializes electrical stimulation/neuromodulation technology. Company products include RecoveryRx, ActiPatch Musculoskeletal Pain Relief, and Others.